SCHEMBL7869153

SCHEMBL7869153

CCS(=O)(=O)CC(CC1CCCCC1)NCc1ccc(C(=O)NC(CCSC)C(=O)O)c(-c2ccccc2C)c1.[LiH]

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7869150 1.00
Lithium Ion SCHEMBL7869147 0.92
SCHEMBL7870238 0.92
SCHEMBL7870235 0.92
SCHEMBL6645514 0.92
SCHEMBL628619 0.91
SCHEMBL628620 0.91
SCHEMBL7870179 0.90 FNTA (0.68)
SCHEMBL7870175 0.90 FNTA (0.68)
SCHEMBL6648138 0.90 FNTA (0.52)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6310095-B1 INHIBITING OR TREATING CANCER, TREATING INTIMAL HYPERPLASIA ASSOCIATED WITH RESTENOSIS AND ATHEROSCLEROSIS, INHIBITING POST-TRANSLATIONAL MODIFICATION OF ONCOGENIC RAS PROTEIN BY PROTEIN FARNESYLTRANSFERASE AND/OR GERANYLGERANYLTRANSFERASE UNIVERSITY OF PITTSBURGH 2001-10-30 US disclosed